MTOR and glioma: Alterations in these metabolites may have considerable potential as non-invasive biomarkers for monitoring response to PI3K/mTOR inhibitors in early phase clinical trials in children with glioma, thereby helping to optimize dosing and treatment of this disease which has devastatingly poor prognosis.